[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100438330":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":31,"centralContacts":35,"locations":42,"responsibleParty":59,"collaborators":22,"id":63,"slug":22,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":22,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":22,"overallStatus":45,"whyStopped":22,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Milton S. Hershey Medical Center","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Exercise Arm 1","EXPERIMENTAL","Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 750 MET-min\u002Fwk for 3-5 days per week, 22-45 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.",[13],"Behavioral: Exercise",{"label":15,"type":10,"description":16,"interventionNames":17},"Exercise Arm 2","Aerobic exercise will be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking and dynamic exercises. A 5-min walking cool down will end the session. The training dose for this arm is 1,000 MET-min\u002Fwk for 3-5 days per week, 30-60 minutes per session at a moderate to vigorous intensity. The exercise can be completed in person or virtually.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Standard of Care","NO_INTERVENTION","This group will receive best NASH clinical practices counseling at baseline and end-of-trial in accordance with NAFLD clinical practice guidelines and be reinforced by handouts from the American Liver Foundation.",null,[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"BEHAVIORAL","Exercise","Aerobic exercise can be completed by walking, jogging or running or by using cardio equipment (e.g., recumbent bike). Each session will begin with a warm-up with walking (30-40% target HR for 5-min) and dynamic exercises (knee-to-chest, 10-yd lateral shuffle, bent over twist, calf sweeps, leg swings). A 5-min walking cool down will end the session (30-40% target HR).",[9,15],[30],"Physical activity",[32],{"name":33,"affiliation":5,"role":34},"Christopher Sciamanna, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Breianna L Hummer, MS","CONTACT","7175310003","320223","bhummer@pennstatehealth.psu.edu",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Penn State Hershey Medical Center","RECRUITING","Hershey","Pennsylvania","17033","United States",{"type":51,"coordinates":52},"Point",[53,54],-76.65025,40.28592,{"lat":54,"lon":53},[57,58],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},{"name":33,"role":34,"phone":22,"phoneExt":22,"email":22},{"type":34,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":62,"oldNameTitle":22,"oldOrganization":22},"Christopher Sciamanna, MD, MPH","Professor, Department of Medicine and Public Health Sciences","Penn State Health Milton S Hershey Medical Center","100438330",false,"NCT04987879","NASH AMPK Exercise Dosing (AMPED) Trial","AMPED","Inclusion Criteria:\n\n* Age 18-69 years\n* Sedentary \\[\\\u003C90 min\u002Fwk of exercise identified by the Get Active Questionnaire (GAQ)\n* BMI \\>25kg\u002Fm2\n* Liver biopsy within six months prior to enrollment showing:\n\n  * NASH defined by NASH Clinical Research Network (CRN) histology scoring system (NAS) \\>4 and MRI-PDFF \\>5% and;\n  * Liver fibrosis stage 1-3\n\nExclusion Criteria:\n\n* Active cardiac symptoms\n* Body mass index (BMI) \\>45kg\u002Fm2\n* Cancer that is active\n* Inability to walk \\>2 blocks\n* Institutionalized\u002Fprisoner\n* Other liver disease\n* Pregnancy\n* Secondary hepatic steatosis\n* Severe comorbidities\n* AUDIT-C questionnaire identified significant alcohol use\n* Substance abuse\u002Factive smoking\n* Uncontrolled diabetes (changes in drug dosing over previous three months or A1c \\>9%)\n* GAQ response indicates exercise may be unsafe.","ALL","18 Years","69 Years",{"count":73,"type":74},45,"ESTIMATED","INTERVENTIONAL",[77],"NA","There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD.\n\nWhile physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.",[80],"NAFLD","2025-10-10",{"date":83,"type":84},"2025-10-14","ACTUAL",{"date":86,"type":84},"2022-08-30",{"date":88,"type":74},"2026-07-15",{"name":5,"class":6},1]